Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Minzasolmin - UCB

Next Previous
Search
Drug Profile

Minzasolmin - UCB

Alternative Names: DLX-313; UCB-0599

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuropore Therapies
  • Developer Neuropore Therapies; UCB Biopharma
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 15 Apr 2025 USB Biopharma terminates a phase II trial for Parkinson's disease (In adults, In the elderly, Early stage disease) in USA, Canada, France, Germany, Italy, the Netherlands, Poland, Spain, United Kingdom (PO), as the decision was made to stop development of minzasolmin (NCT05543252)
  • 17 Nov 2024 UCB Biopharma completes phase I trial (In volunteers) in the Germany (PO) (NCT06533475)
  • 06 Sep 2024 UCB Biopharma SRL completes a phase-II clinical trials in Parkinson's disease (Early-stage disease, In the elderly, In adults) in the US, Canada, France, Netherlands, United Kingdom, Spain, Poland, Italy and Germany (PO) (NCT04658186) (EudraCT2020-003265-19)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top